The Food and Drug Administration has declined to review Moderna’s application for the first mRNA-based flu vaccine, a decision that shocked the company and that comes as the agency plans to tighten ...
April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results